SAMSUNG PHARMACEUTICAL.CO.,Ltd. Statistics
Want to see KR:001360 full AI Analyst Report?
SAMSUNG PHARMACEUTICAL.CO.,Ltd. (001360) Stock Statistics & Valuation Metrics
Total Valuation
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has a market cap or net worth of KRW 124.62B. The enterprise value is KRW 134.50B.
- Market Cap
- KRW 124.62B
- Enterprise Value
- KRW 134.50B
Share Statistics
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has 94,162,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 94,162,080
- Owned by Insiders
- ―
- Owned by Institutions
- 0.40%
Financial Efficiency
SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is -13.63%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- -13.63%
- Return on Capital Employed (ROCE)
- -0.16
- Revenue Per Employee
- 191.98M
- Profits Per Employee
- 48.10M
- Employee Count
- 240
- Asset Turnover
- 0.28
- Inventory Turnover
- 3.07
Valuation Ratios
The current PE Ratio of SAMSUNG PHARMACEUTICAL.CO.,Ltd. is -0.85. SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s PEG ratio is -0.42.
- PE Ratio
- -0.85
- PS Ratio
- 2.73
- PB Ratio
- 1.61
- Price to FCF
- -11.95
- Price to Operating Cash Flow
- -13.24
- PEG Ratio
- -0.42
Income Statement
In the last 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. had revenue of 46.07B and earned 11.55B in profits. Earnings per share was 122.66.
- Revenue
- 46.07B
- Gross Profit
- 14.64B
- Operating Income
- -19.46B
- Pretax Income
- 11.55B
- Net Income
- 11.55B
- EBITDA
- -18.06B
- Earnings Per Share (EPS)
- 122.66
Cash Flow
In the last 12 months, operating cash flow was -8.80B and capital expenditures -13.48B, giving a free cash flow of -9.75B billion.
- Operating Cash Flow
- -8.80B
- Free Cash Flow
- -9.75B
- Free Cash Flow per Share
- -103.61
Dividends & Yields
SAMSUNG PHARMACEUTICAL.CO.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.37%
- Earnings Yield
- -117.71%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- -12.94%
- 50-Day Moving Average
- 1313.34
- 200-Day Moving Average
- 1541.53
- Relative Strength Index (RSI)
- 44.61
- Average Volume (3m)
- 323.96K
Important Dates
SAMSUNG PHARMACEUTICAL.CO.,Ltd. upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
SAMSUNG PHARMACEUTICAL.CO.,Ltd. as a current ratio of 0.92, with Debt / Equity ratio of 14.62%
- Current Ratio
- 0.92
- Quick Ratio
- 0.68
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -0.36
- Interest Coverage Ratio
- -16.28
Taxes
In the past 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
SAMSUNG PHARMACEUTICAL.CO.,Ltd. EV to EBITDA ratio is -8.17, with an EV/FCF ratio of -13.39.
- EV to Sales
- 3.06
- EV to EBITDA
- -8.17
- EV to Free Cash Flow
- -13.39
- EV to Operating Cash Flow
- -14.84
Balance Sheet
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has KRW 9.56B in cash and marketable securities with KRW 18.60B in debt, giving a net cash position of -KRW 9.04B billion.
- Cash & Marketable Securities
- KRW 9.56B
- Total Debt
- KRW 18.60B
- Net Cash
- -KRW 9.04B
- Net Cash Per Share
- -KRW 96.03
- Tangible Book Value Per Share
- KRW 598.85
Margins
Gross margin is 38.51%, with operating margin of -39.32%, and net profit margin of -320.93%.
- Gross Margin
- 38.51%
- Operating Margin
- -39.32%
- Pretax Margin
- -320.93%
- Net Profit Margin
- -320.93%
- EBITDA Margin
- -37.40%
- EBIT Margin
- -39.32%
Analyst Forecast
The average price target for SAMSUNG PHARMACEUTICAL.CO.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.43%
- EPS Growth Forecast
- -234.71%
Scores
- Smart Score
- ―
- AI Score
- 44

